Press Releases

 

 

 

Press Releases

 

Roche Pharma India Launches Patient Support App To Help Patients Seamlessly Navigate Their Care Journey

Roche expands its Global Analytics and Technology Center of Excellence.

Roche's Evrysdi (Risdiplam) - the first and only oral treatment for adults and children two months or older suffering from Spinal Muscular Atrophy (SMA) now available in India.

Roche’s Antibody Cocktail (Casirivimab and Imdevimab) is now available in India, Cipla to market it pan-India

Roche receives Emergency Use Authorisation in India for its investigational Antibody Cocktail (Casirivimab and Imdevimab) used in the treatment of Covid-19

Company statement on Tocilizumab (Brand: Actemra) supplies

US-FDA Approved Foundation Medicine's foundationone®Liquid cdx, a Pan-Tumor Liquid Biopsy Genomic Test for Late Stage Cancer Patients now Available in India

Roche Pharma India expands partnership with Cipla to further improve access to key oncology medicines

Roche Pharma India partners with Entero Healthcare Solutions to improve access to nephrology medicines

V. Simpson Emmanuel appointed as General Manager, Roche Products (India) Pvt. Ltd.

Roche’s Atezolizumab receives DCGI approval for treatment of metastatic triple-negative breast cancer in India

Roche’s Atezolizumab receives DCGI approval for treatment of extensive-stage small cell lung cancer in India

Roche launches new therapy Emicizumab for people with Hemophilia A on World Hemophilia Day

Roche and St. Jude India ChildCare Centre come together with Dr. B Barooah Cancer Institute to offer holistic cancer care to underprivileged children

Roche Pharma India partners with Cipla to create greater access to key medicines

Key Statements

 

Key statement on the emergency use authorisation and supply of the investigational antibody cocktail casirivimab and imdevimab in India.

Roche's statement on Tocilizumab (Actemra) supplies

An Opportunity for India: Improving Transparency

Providing confidence and support to patients

Approval of biosimilars must be subject to rigorous clinical and regulatory standards.

Company Statement: Delhi High Court Interim Order, March 03, 2017